SCHEMBL987145

SCHEMBL987145

c1ccc(C[Si](c2ccccc2)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 1/20 0.43
TSHR P16473 4/20 0.40
ALDH1A1 P00352 3/20 0.40
LOXL2 Q9Y4K0 2/20 0.39
IDO1 P14902 1/20 0.39
TP53 P04637 1/20 0.39
TRPA1 O75762 1/20 0.39
NR1H2 P55055 2/20 0.38
NR1H3 Q13133 2/20 0.38
MAOB P27338 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
ALOX12 P18054 1/20 0.38
CASP1 P29466 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TAAR1 Q96RJ0 2/20 0.37
AOC3 Q16853 1/20 0.37
TDP1 Q9NUW8 2/20 0.36
CYP2A6 P11509 1/20 0.36
HTR2A P28223 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22374958 0.85 NR1H2 (0.34) CALM1TSHRALDH1A1NR1H2NR1H3
SCHEMBL29168473 0.84 ALDH1A1 (0.42) TSHRALDH1A1IDO1TAAR1TDP1
SCHEMBL989099 0.84 LMNA (0.42) TSHRIDO1TP53HPGDALOX12
SCHEMBL14208869 0.82 LMNA (0.41) TSHRIDO1TP53HPGDALOX12
SCHEMBL19020413 0.80 LMNA (0.43) ALDH1A1NR1H2NR1H3HPGDALOX12
SCHEMBL25491508 0.79 ESRRG (0.41) ALDH1A1TP53NR1H2NR1H3HPGD
SCHEMBL19849752 0.77 LMNA (0.38) TSHRIDO1TP53HPGDALOX12
SCHEMBL29015040 0.77 LMNA (0.44) ALDH1A1ALOX12TAAR1SMN1; SMN2
SCHEMBL13347012 0.74 TDP1 (0.50) ALDH1A1LOXL2MAOBHPGDALOX15
SCHEMBL10318779 0.74 CYP19A1 (0.43) CALM1TSHRALDH1A1LOXL2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024144241-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME 솔루스첨단소재 주식회사 2024-07-04 WO disclosed
CN-112593212-B Method for forming topologically selective silicon oxide film by cyclic plasma enhanced deposition process ASM IP私人控股有限公司 2023-12-22 CN disclosed
WO-2023222245-A1 PROCESS FOR PRODUCING ORGANOSILICON COMPOUNDS WACKER CHEMIE AG (DE) 2023-11-23 WO disclosed
CN-112593212-A Method for forming topologically selective silicon oxide films by cyclic plasma enhanced deposition process ASM IP私人控股有限公司 2021-04-02 CN disclosed
EP-2275427-B1 Ruthenium-diamine complex and methods for producing optically active compounds TAKASAGO PERFUMERY CO LTD (JP) 2013-09-11 EP disclosed
US-8404879-B2 Ruthenium-diamine complex and methods for producing optically active compounds TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-03-26 US disclosed
EP-2258707-B1 Ruthenium silyl-arene complexes, and method for production thereof TAKASAGO PERFUMERY CO LTD (JP) 2013-03-06 EP disclosed
WO-2011160758-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2011-12-29 WO disclosed
US-7880025-B2 complexing trimethyl(4-methyl-1,4-cyclohexadienyl)silane with ruthenium chloride to produce RuCl2 [trimethyl (4-methyl-1,4-cyclohexadienyl) silane] TAKASAGO INTERNATIONAL CORPORATION (JP) 2011-02-01 US disclosed
EP-2275427-A1 Ruthenium-diamine complex and methods for producing optically active compounds Takasago International Corporation (JP) 2011-01-19 EP disclosed
US-20110009646-A1 RUTHENIUM-DIAMINE COMPLEX AND METHODS FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS TAKASAGO INTERNATIONAL CORPORATION (JP) 2011-01-13 US disclosed
EP-2258707-A1 Ruthenium silyl-arene complexes, and method for production thereof Takasago International Corporation (JP) 2010-12-08 EP disclosed
US-20100298588-A1 RUTHENIUM SILYL-ARENE COMPLEX , AND METHOD FOR PRODUCTION THEREOF TAKASAGO INTERNATIONAL CORPORATION (JP) 2010-11-25 US disclosed
EP-1431314-B1 process for the living radical polymerization of olefinically unsaturated monomers ENI SPA (IT) 2005-11-16 EP disclosed
EP-1431314-A2 Process for the living radical polymerization of oliffinically unsaturated monomers ENI S.p.A. (IT) 2004-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298588-A1 RUTHENIUM SILYL-ARENE COMPLEX , AND METHOD FOR PRODUCTION THEREOF SPR, LSS, SRI CALM1 2027/4885TSHR 4573/4885ALDH1A1 2369/4885
US-20110009646-A1 RUTHENIUM-DIAMINE COMPLEX AND METHODS FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS ADH5, AOC1, ADH1A CALM1 4208/4885TSHR 2921/4885ALDH1A1 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.